A recent breakthrough study published in npj Vaccines offers a promising new direction in the global fight against polio. Researchers have developed a recombinant trivalent poliovirus virus-like particle (VLP) vaccine candidate using the yeast Pichia pastoris, produced through tightly controlled fermentation. Crucially, this approach avoids the need to cultivate live virus, mitigating the biosafety risks associated with current inactivated (IPV) and live-attenuated (OPV) vaccines.

The significance of this work lies not only in its potential to produce safer, effective polio vaccines but also in its scalability, compatibility with existing manufacturing infrastructure, and its capacity for use in low- and middle-income countries. The authors demonstrated that the yeast-derived VLPs were structurally and immunogenically comparable, and in some respects superior to IPV, especially when combined with an adjuvant. Notably, these VLPs retained the critical D antigen conformation required to trigger a protective immune response and outperformed IPV in potency assays.

At the heart of this innovation is the challenge of maintaining structural integrity through every step of the production process, and that's where the role of cell disruption becomes critical.

Consistent, Controlled Cell Disruption: The Foundation of Integrity

To access the intracellular VLPs post-fermentation, the researchers employed mechanical lysis using a CF1 high-pressure cell disruptor from Constant Systems, a platform we proudly support and distribute at BPES. The lysates were generated under controlled pressure (40 kpsi), chilled to 4 °C to prevent protein denaturation and preserve the native conformation of the viral capsid proteins. This was a deliberate choice; the preservation of D antigen structure is essential for downstream immunogenicity.

This use case exemplifies why Constant Systems disruptors are considered the gold standard for high-integrity cell lysis in vaccine development and structural biology:

• Highly Controlled Pressure Application: Ensures reproducible rupture of cell walls across batches.
• In-Process Cooling: Prevents heat-induced protein denaturation, crucial when the goal is to preserve the native structure of complex particles like VLPs.
• Scalable & Repeatable Results: Whether in lab-scale optimisation or industrial fermentation, consistent performance enables seamless scale-up.

Why It Matters

As the world moves toward complete polio eradication, biosafety concerns around existing vaccine production processes have never been more pressing. VLP-based vaccines offer a safer and scalable solution, and their successful development depends heavily on each upstream and downstream step, especially cell lysis. The research from the University of Leeds and partners shows how platform precision, from fermentation to cell disruption, underpins the quality and viability of next-generation vaccines.

We work closely with research and industrial partners across the biotech and biopharma sectors to provide fit-for-purpose equipment that meets the rigour of regulated bioprocessing. The Constant Systems platform is widely recognised as the gold standard for cell lysis, not only for its precise pressure control and reproducibility, but also for its ability to maintain native structure and biological activity through a highly controlled and contained disruption process with integrated sample cooling.

This study is an excellent example of how thoughtful upstream and downstream integration, powered by technologies like the CF1, can accelerate the translation of promising research into globally impactful solutions. Read it below: